Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 12/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510956 | 0.98 | DGAT1 (1.00) | DGAT1LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4510806 | 0.90 | DGAT1 (0.81) | DGAT1LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4508757 | 0.89 | DGAT1 (0.83) | DGAT1LMNA | |
| SCHEMBL4506673 | 0.88 | DGAT1 (0.81) | DGAT1LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4496999 | 0.87 | DGAT1 (0.80) | DGAT1LMNAMAPTSMN1; SMN2HDAC1 | |
| SCHEMBL4512985 | 0.86 | DGAT1 (0.75) | DGAT1LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4507714 | 0.84 | DGAT1 (0.72) | DGAT1LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL13755344 | 0.83 | DGAT1 (1.00) | DGAT1LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3541079 | 0.82 | DGAT1 (0.82) | DGAT1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4512056 | 0.79 | DGAT1 (0.68) | DGAT1LMNAMAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215779-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | claimed |
| US-20090215779-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215779-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT2, GPR119, DGAT1 | DGAT1 3/4885LMNA 3179/4885MAPT 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.